Find Jobs | Post Resume | my careerbuilder | Help
Employer Quick Look

Ferring Pharmaceuticals

2,500 - 5,000 employees  |  
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis.The company's research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body's own terms to enable doctors to combat numerous diseases and medical conditions.The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.

Ferring has its own production facilities in several European countries, in South America, Israel and China and is currently building new facilities in the US and India. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing. Ferring's marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 50 countries and employ more than 4500 people throughout the world, while treatments are available in more than 90 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.

Ferring's R&D projects complement Ferring's product portfolio and will add a new generation of products to some of the company's most successful specialty brands. R&D facilities are located in Denmark, USA, Israel, India and China. Ferring is committed to a future where it will continue to provide new and innovative medicines by utilizing existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.

Ferring Pharmaceuticals Inc (FPI)
Ferring Pharmaceuticals Inc. is a subsidiary of Ferring pharmaceuticals, a privately owned, global pharmaceutical company. Ferring Pharmaceuticals offers a line of products in the U.S. market. They include: BRAVELLE® (urofollitropin for injection, purified), MENOPUR® (menotropins for injection, USP) and REPRONEX® (menotropins for injection, USP), NOVAREL® (chorionic gonadotropin for injection, USP), ENDOMETRIN®(progesterone) Vaginal Insert, LYSTEDA® (tranexamic acid tablets), FIRMAGON® (degarelix for injection), and EUFLEXXA® (1% sodium hyaluronate). Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/ gynecology, orthopaedics and urology.

Ferring Pharmaceuticals Inc. recently announced the purchase of a 25 acre site in Parsippany, NJ. The U.S. Operations Center will be a fully integrated pharmaceutical facility that will house management, administration, and support, commercial operations, manufacturing and product development. It will include a state-of-the art manufacturing suite, next-generation product development laboratories, a fully equipped education and training conference center, and administrative offices.

Ferring Pharmascience Center US (FIPCUS)
Ferring International PharmaScience Center, Inc. (FIPCUS), was formed in 2008 as the drug development subsidiary for Ferring Pharmaceuticals Inc. FIPCUS is responsible for U.S. Clinical R & D for both local projects (those intended for U.S. commercialization alone) as well as Global projects. As an organization, it is charged with rapid identification, development, and commercialization of products in the clinical specialty areas of Infertility, Orthopedics, Gastroenterology, and Urology.

Ferring Research Institute (FRI)
Ferring Research Institute, Inc. (FRI) is the company’s center of excellence for peptide research. Established in San Diego in 1996, FRI now occupies a company-owned, state-of-the-art research facility in Sorrento Valley. Located in the heart of the Southern California biopharmaceutical community, the center.
Career Opportunities
Ferring considers recruitment as an investment in the future. Our recruitment process is intense, challenging and we are passionate about identifying true leaders. Leaders of people, projects, processes and products.

We aim to attract, select and retain people of the highest quality who have the talent and the potential to progress within the company.

Ferring fully recognizes that the performance of its employees are fundamental to long-term success.
Research & Development
Ferring’s R&D activities are focused on the following key therapy areas: reproductive health, urology, gastroenterology and endocrinology. Ferring is a world leader in peptide and peptidomimetic research and this forms an important part of the history of the company. In addition, in all therapy areas, Ferring pays particular attention to developing drug delivery systems that are effective and convenient for the patient.

Specifically, Ferring aims to produce new innovative drugs and to improve existing therapies by:
  • Focusing on novel peptide/hormone and protease genes;
  • Further developing peptide and peptidomimetic science and technology;
  • Adapting existing peptide based medications to meet specific medical needs;
  • Developing effective and patient friendly drug delivery systems.

As well as conducting R&D through the four Ferring research centers, Ferring also undertakes research collaboration with scientific research institutes, universities and pharmaceutical and biotechnology companies across the world. This cooperation takes place whenever it can help to achieve the end goal of the R&D work and will be beneficial for both parties.